Programme
Wednesday, October 16, 2013 |
||
15:30 – 17:00 |
Registration & Reception |
|
17:00 – 17:15 |
Opening Comments |
|
Discovery Re-Invented |
||
17:15 – 18:00 |
Steve Young |
HIV Integrase Inhibitors: The Chemistry Behind The Discovery of Isentress |
18:00 – 18:30 |
James Breitenbucher |
Drug Discovery – What really needs to be “Re-Invented”? |
18:30 – 19:00 |
Bart DeCorte |
The Janssen Incubator – A Novel Business Model to Spark Internal Innovation |
19:00 - 20:00 |
Welcome Reception/Dinner |
|
Novel Pharma Approaches |
||
20:00 – 20:30 |
Patrick Lam |
Discovery of Eliquis®/Apixaban, a novel FXa anticoagulant |
20:30 – 21:00 |
Serge Boulet |
Phenotypic Drug Discovery of Novel Anti-Angiogenics |
21:00 – 21:30 |
Gabor Butora |
Chemically Modified Oligonucleotides for RNAi |
21:30 -22:00 |
Michael Trzoss |
Novel GyrB/ParE Inhibitors |
|
Free Time |
Thursday, October 17, 2013 |
||
06:00 – 08:00 |
Breakfast |
|
Collaborative Drug Discovery I |
||
08:00 – 08:45 |
Michael Foley |
TBA |
08:45 – 09:15 |
Craig Thomas |
Associative Data Profiles Connect Basic Research to Translational Efforts |
09:15 – 09:45 |
Todd Chappell |
Entrepreneurs-in-Residence, Not Just for Venture Capitalists |
09:45 – 10:15 |
James Barrow |
Genetics-Driven Psychiatry Drug Discovery |
10:15 – 10:30 |
Greg Miknis |
Promoting Colorado Drug Discovery Research: Creation of the Colorado Center for Drug Discovery (C2D2) |
10:30 – 11:00 |
Refreshments |
|
11:00 – 11:30 |
Joseph Vacca |
Drug Discovery in the 21st Century |
11:30 – 12:00 |
Zhengying Pan |
Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase |
12:00 – 12:15 |
Barry Bunin |
Collaborative Drug Discovery Technology Neglected, Infectious, CNS, and Repositioning Applications |
12:15 – 12:30 |
Olanrewaju Omobuwajo |
Fertility reducing effect of pandanus candelabrum p.beauv. Leaves in male wistar rats |
12:30 – 13:15 |
Group Lunch |
|
12:30 – 16:30 |
Free Time |
|
Natural Products |
||
16:30 – 16:45 |
Michael Goetz |
The Natural Products Discovery Institute. Classical and novel approaches to drug discovery |
16:45 – 17:30 |
Sean Brady |
Watch where you step, there is new chemistry everywhere |
17:30 – 18:00 |
Jef De Brabander |
Opportunities for Lead Discovery in a Biomedical Research Environment |
18:00 – 18:20 |
Guy Carter Biosortia Pharmaceuticals |
A deep dive into aquatic microbial consortia for drug discovery |
18:20 – 18:40 |
Jetze Tepe
|
Non-competitive regulation of the human proteasome by natural products and natural product inspired scaffolds |
18:40 – 19:00 |
Phillip Cox Noramco |
Development of poppy varieties to suit changing market requirements |
19:00 – 20:00 |
Group Dinner |
|
20:00 – 22:00 |
Poster Session & Cocktail Reception |
Friday, October 18, 2013 |
||
06:00 – 08:00 |
Breakfast & Free Morning |
|
12:00 – 12:45 |
Group Lunch |
|
Structure, Modeling and Informatics |
||
12:45 13:30 |
William Jorgensen |
Drug Discovery Accelerated by Computational Methods |
13:30 – 14:00 |
Kenneth Merz |
Blurring to Bring Binding Free Energies into Focus |
14:00 – 14:30 |
Chris Williams |
Water Placement - Application of 3D-RISM to structure-based drug design |
14:30 – 14:45 |
Christopher Reynolds |
Unravelling similarities between class A and class B GPCRs through modelling and mutagenesis |
14:45 – 15:00 |
Lance Westerhoff |
Quantum mechanics-based macromolecular x-ray refinement as an advanced method for the high throughput crystallography |
15:00 – 15:30 |
Leah Frye |
Nimbus and Schrödinger Reinventing Drug Discovery: Rapid and Efficient Development of Acetyl-CoA Carboxylase Inhibitors |
15:30 – 16:00 |
Paul Leeson |
Compound Quality: What Have We Learned? |
16:00 - 16:30 |
Refreshments |
|
Biologics and Non-traditional Therapeutics |
||
16:30 – 17:15 |
David Lowe |
Targeting the Amino Acid Dependence of Cancer |
17:15 – 17:45 |
Andreas Bader |
MRX34 – from bench to bedside |
17:45 – 18:15 |
David Gorenstein |
Next Generation X-Aptamers for Personalized Nanomedicine |
18:15 – 18:45 |
Aaron Sato |
Rapid Design and Production of Homogeneous Best-in-Class Protein Therapeutics using Cell-Free Protein Expression |
18:45 – 19:00 |
Ian Pottie Mount Saint Vincent University |
Developing an Imaging Agent for Cholinesterase Enzymes to Diagnose Alzheimer’s Disease |
19:00 – 19:30 |
Refreshments |
|
Foundation Support for Neglected Diseases |
||
19:30 – 20:15 |
Omar Vandal |
Partnerships in Drug Discovery and Technology Development for Diseases of the Developing World |
20:30 – 00:00 |
*Gala Night, Group Photo & Poster Awards* |
Saturday, October 19, 2013 |
||
07:00 – 09:00 |
Breakfast |
|
09:00 |
Chair Opening |
|
Discovery Technologies |
||
09:00 – 09:20 |
Dietmar Wolf AnalytiCon |
Novel Macrocyclic Libraries Evolved from Natural Product Technology Platforms |
09:20 – 09:40 |
Prem Premsrirut |
RNAi mouse models: Revolutionizing drug discovery in vivo |
09:40 – 10:00 |
Philip Jones |
Institute for Applied Cancer Science, developing the next generation of oncology agents for targeted patient populations |
10:00 – 10:30 |
Matthew Segall |
Finding and Applying Rules for Successful Drug Discovery |
10:30 – 11:00 |
Refreshments |
|
11:00 – 11:30 |
Janet Ralbovsky |
Technology Transfer Re-invented: How is Academia Adapting to the Changes in Drug Discovery? |
11:30 – 12:00 |
Joel Dudley Mount Sinai School of Medicine |
Developing a Systematic Computational Approach to Identify Novel Drug Indication Relationships Using Public Gene Expression Profiles |
12:00 – 12:45 |
Group Lunch |
|
Collaborative Drug Discovery II |
||
12:45 – 13:15 |
Benjamin Blass |
Drug Discovery in the Academic Community |
13:15 – 13:45 |
Mark McDonnell |
Riluzole prodrugs for melanoma and ALS |
13:45 – 14:15 |
Sandhya Kortagere |
Designing protein-protein interaction inhibitors as novel antimalarial chemotherapeutics |
14:15 – 14:30 |
Peter Cheuka |
Synthesis of aminomethylthiazole analogues for evaluation as antiplasmodial agents |
14:30 – 15:00 |
Kris Josephson |
Discovery of Potent Macrocyclic Peptides for Drug Development |
15:00 – 15:15 |
Closing Remarks (Chairs & Fusion) |
|
15:15 |
Departures |